Effect of deep brain stimulation in treatment of Alzheimer's disease

Evaluating the effect of deep brain stimulation (DBS) on neuropsychiatric tests parameters deviation and hippocampal volumetry in patients with Alzheimer's disease (AD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240903062942N1

Enrollment

Registered

2024-09-27

Start date

2024-09-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease. Alzheimer's disease, unspecified

Interventions

Intervention group: Deep Brain Stimulation.

Eligibility

Sex/Gender

All

Age

45 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with possible Alzheimer's criteria according to the National Alzheimer's Institute and CDR global scales and ADAS Cog 11

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Neuropsychological cognition disorder. Timepoint: Measurement of cognitional disorders at First (before surgery), 6 and 12 month after procedure. Method of measurement: MMSE clinical test.;Neuropsychological cognition disorder. Timepoint: At first (before procedure), 6 and 12 month after procedure. Method of measurement: ADAS-cog clinical test.;Hippocampal volumetry. Timepoint: At first (before procedure), 6 and 12 month after procedure. Method of measurement: MRI.;CSF Beta Amyloid. Timepoint: At first (before procedure), 6 and 12 month after procedure. Method of measurement: ELISA test.	—

Measure

Time frame

Neuropsychological cognition disorder. Timepoint: Measurement of cognitional disorders at First (before surgery), 6 and 12 month after procedure. Method of measurement: MMSE clinical test.;Neuropsychological cognition disorder. Timepoint: At first (before procedure), 6 and 12 month after procedure. Method of measurement: ADAS-cog clinical test.;Hippocampal volumetry. Timepoint: At first (before procedure), 6 and 12 month after procedure. Method of measurement: MRI.;CSF Beta Amyloid. Timepoint: At first (before procedure), 6 and 12 month after procedure. Method of measurement: ELISA test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRamtin Pourahmad

Tehran University of Medical Sciences

Ramtinpourahmad79@gmail.com+98 21 4489 7836

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026